New Results From ARTEN Study of Nevirapine Plus Tenofovir and Emtricitabine (TDF/FTC) Versus Boosted Protease Inhibitor Regimen of Atazanavir/Ritonavir Plus TDF/FTC Revealed
CAPE TOWN, South Africa , July 20 /PRNewswire/ -- New data became available today at the 5(th) International AIDS Society Conference from ARTEN ( A tazanavir/ R itonavir on a background of T enofovir and E mtricitabine [Truvada(R)] versus N evirapine). ARTEN is an open-label, multi-c...
Chipscreen and HUYA Bioscience to Present Clinical Data on Novel HDAC Inhibitor at the 2009 ASCO Annual Meeting
SHENZHEN, China and SAN DIEGO, May 28 /PRNewswire/ -- Shenzhen Chipscreen Biosciences, Ltd., and HUYA Bioscience International, LLC, today announced that final data from a Phase 1 trial conducted by Chipscreen of the investigational compound chidamide (CS055/HBI-8000) will be presented at the 2009...
Scientific Data Relating to Cinryze(TM) Presented at 6th Annual C1 Inhibitor Deficiency Workshop
BUDAPEST, Hungary and EXTON, Pa., May 26 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM ) today announced the presentation of five abstracts relating to Cinryze(TM) (C1 esterase inhibitor
[human]) therapy at the 6th Annual C1 Inhibitor
Cinryze was appr...
New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI)
PHILADELPHIA, May 22 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY ), the global specialty biopharmaceutical company, announced results of a study showing that coadministration of the ADHD medication VYVANSE(R) (lisdexamfetamine dimesylate) CII with the proton pump inhibitor
TargeGen Announces Successful Completion of Patient Enrollment in Clinical Trial of JAK2 Inhibitor TG101348 in Myelofibrosis Patients and Scheduled Presentation of Preliminary Trial Data at EHA Conference in Berlin
SAN DIEGO, May 14 /PRNewswire/ -- TargeGen, Inc. today announced that the Company successfully completed enrollment of a multi-center clinical trial of TG101348, an oral, potent, and highly selective inhibitor
of JAK2 in patients with myelofibrosis on May 7, 2009.
FDA Accepts Arno Therapeutics' IND for AR-12 a PDK1 Inhibitor That Blocks the PI3K/Akt Pathway
PARSIPPANY, N.J., May 11 /PRNewswire-FirstCall/ -- Arno Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on oncology therapeutics, today announced that the U.S. Food and Drug Administration ("FDA") accepted the Company's Investigational New Drug ("IND") application for the us...
Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C
Start of trial triggers $10 million milestone payment to Pharmasset
PRINCETON, N.J., April 24 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS ) and Roche (Roche SWX: RO, ROG; Pink Sheets: RHHBY) today announced that the first patient has been dosed in a Phase IIb study of R7128, th...
Cylene to Present Advances in its Oral Inhibitor of CK2 at AACR Annual Meeting
SAN DIEGO, April 17 /PRNewswire/ -- Cylene Pharmaceuticals announced today that it will be presenting new data on recent advances of its small molecule anticancer agents during a symposium and several poster presentations at the American Association for Cancer Research (AACR) annual meeting, to be...
Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma
SUNNYVALE, Calif., April 13 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc.
(Nasdaq: PCYC ) today announced that it has begun treating patients in a Phase
1 dose-escalation study to evaluate the safety and tolerability of PCI-32765,
an orally available, selective inhibitor
of Bruton's tyrosine ...
Another LNA-based RNA Inhibitor Enters Clinical Trials
COPENHAGEN, March 20 /PRNewswire/ -- Santaris Pharma announced today that
the fourth LNA-based drug has been brought into the clinic. In the USA
several patients with cancer have now been treated with the Company's
Survivin inhibitor, which is jointly developed by Santaris Pharma and Enzon
FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE)
- PDUFA Date for Cinryze for Acute HAE Indication is June 3, 2009 -
EXTON, Pa., Feb. 3 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM ) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review for Cinryze C1 Inhibitor
(human) as a trea...
Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2
SAN DIEGO, Jan. 5 /PRNewswire/ -- Cylene Pharmaceuticals announced today that it has initiated a Phase I clinical trial of its oral CK2 protein kinase inhibitor, CX-4945, in patients with advanced solid tumors, Castleman's disease, or multiple myeloma. The primary endpoints of the oral dose escala...
Video: Femara(R) First Aromatase Inhibitor to Indicate Survival Benefit Versus Tamoxifen When Taken for Five Years After Breast Cancer Surgery
- Femara showed reduced risk of death by 13% (P=0.08), despite inclusion of patients crossing over from tamoxifen to Femara therapy
- In a separate censored analysis excluding patients after they crossed over to Femara, reduction in risk of death was 19%
- Long-term follow-up fro...
TargeGen Affiliates Scheduled for Oral Presentation of Interim Clinical Trial Data at 2008 ASH Meeting in San Francisco for TG101348, a Potent, Selective, Oral JAK2 Inhibitor in Myeloproliferative Disease Patients
SAN DIEGO, Dec. 1 /PRNewswire/ -- TargeGen has announced that an oral
presentation of preliminary results from a multi-center, US-based clinical
trial of TG101348 in myeloproliferative disease patients has been scheduled at
the 2008 American Society of Hematology (ASH) Meeting.
S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis
SINGAPORE, Dec. 1 /PRNewswire/ -- S*BIO Pte Ltd today announced the initiation of a Phase 1/2 clinical trial of SB1518, a potent and orally-active JAK2 inhibitor, in leading medical centers in Australia for patients with chronic idiopathic myelofibrosis (CIMF).
The trial is designed to e...
Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
SUNNYVALE, Calif., Nov. 25 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc.
(Nasdaq: PCYC ) today announced that the company has completed a Phase 1
clinical trial with PCI-27483, the company's novel, first-in-class
small-molecule Factor VIIa inhibitor. The trial was conducted in sixteen (16)
Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
Company reaffirms its innovation leadership and long-term commitment to hepatitis research
KENILWORTH, N.J., Nov. 24 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ) today provided a clinical update on boceprevir, its lead investigational oral hepatitis C protease inhi...
Chipscreen Biosciences and HUYA Bioscience Int'l Announce Promising Preclincial and Phase I Solid Tumor/Lymphoma Data for Chidamide/HBI-8000, New HDAC Inhibitor for Cancer
First Compound Sourced from China Shows Strong Results Presented at Cambridge Healthtech Institute Fall Conference
BOSTON, Oct. 23 /PRNewswire/ -- CHI -- Chipscreen Biosciences
(Chipscreen) and HUYA Bioscience International (HUYA) today described the
preclinical profile and outco...
Cytopia Scientific Presentations on JAK2 Inhibitor Program
MELBOURNE, Australia, Oct. 16 /PRNewswire/ -- Cytopia Limited (ASX:
CYT) will present data on its JAK2 inhibitor
program at two important
scientific meetings this month.
Dr Emmanuelle Fantino, Head of Biology at Cytopia, will present a
lecture entitled Targeted JAK2 Inhibitors for Myeloproli...
S*BIO Initiates U.S. Phase I Clinical Trials of Oral JAK2 Inhibitor SB1518 for the Treatment of Hematological Malignancies
SINGAPORE, Sept. 18 /PRNewswire/ -- S*BIO Pte Ltd today announced the
initiation of multi-center Phase I clinical trials of SB1518, a potent and
orally-active JAK2 inhibitor, in patients with leukemia and certain types
of lymphoma. These first Phase I trials for SB1518 comprise of ascending
Daiichi Sankyo Announces Clinical Study Data for Oral Factor Xa Inhibitor DU-176b
MUNICH, Germany, Sept. 2 /PRNewswire-FirstCall/ -- Data presented today
at the Annual Congress of the European Society of Cardiology showed that
the investigational oral Factor Xa inhibitor
DU-176b reduced the incidence
of venous thromboembolism (VTE) compared with dalteparin among patients
Telik's Proteasome Inhibitor Program Meets a Preclinical Development Milestone
PALO ALTO, Calif., Aug. 21 /PRNewswire-FirstCall/ -- Telik, Inc.
(Nasdaq: TELK ) announced today that its novel small molecule proteasome
inhibitor program met a preclinical development milestone by demonstrating
anticancer activity in preclinical models of human leukemia. The proteasome
Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
SUNNYVALE, Calif., June 9 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc.
(Nasdaq: PCYC ) today announced results from a preclinical study evaluating
PCI-32765, an orally available, selective inhibitor
of Bruton's tyrosine
kinase, or Btk, in collagen induced arthritis, an established animal mod...
Exelixis Reports Positive Clinical Pharmacodynamics Data for PI3K/mTOR Inhibitor XL765 at ASCO
Robust Pathway Inhibition in Tumor and Surrogate Tissues at Well-Tolerated Doses
CHICAGO, May 31 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL )
reported interim data from a phase 1 dose-escalation trial of XL765, a
novel small molecule inhibitor
Human Genome Sciences Initiates First Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Solid Tumors
- Primary study objectives include evaluation of safety and tolerability, as well as selection of a recommended dose for Phase 2 trials -
ROCKVILLE, Md., May 30 /PRNewswire-FirstCall/ -- Human Genome Sciences,
Inc. (Nasdaq: HGSI ) today announced that it has initiated dosing in a Phase
Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program
- Lead Candidate, RDEA806, Demonstrated No Reproductive Toxicity in Preclinical Study -
- RDEA427 Selected as Clinical Candidate, Demonstrated a 40 Hour Half-Life with Potential for Once Daily Oral Dosing -
SAN DIEGO, May 22 /PRNewswire-FirstCall/ -- Ar...
Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
KENILWORTH, N.J., May 21 /PRNewswire-FirstCall/ -- Schering-Plough
Corporation (NYSE: SGP ), a leader in hepatitis research, today announced
that it is initiating two large Phase III studies of boceprevir, its
investigational oral hepatitis C protease inhibitor, in patients
ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
Drug Represents Potential New Approach for the Treatment of Inflammatory Disease Milestone Triggers $10 Million Payment from Partner GlaxoSmithKline
MOUNTAIN VIEW, Calif., May 13 /PRNewswire/ -- ChemoCentryx, Inc., today
announced the initiation of a Phase I cli...
Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
SAN DIEGO, April 17 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals,
Inc. (Nasdaq: ANDS ) presented a late-breaker oral presentation today at the
21st International Conference on Antiviral Research (ICAR) in Montreal,
Quebec, providing updated preclinical data on ANA598, a non-nucleoside
Pharmacyclics' Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
SAN DIEGO and SUNNYVALE, Calif., April 16 /PRNewswire-FirstCall/ --
Pharmacyclics, Inc. (Nasdaq: PCYC ) today presented preclinical results
demonstrating the anti-tumor activity of PCI-27483, the company's
small-molecule Factor VIIa inhibitor. The data were presented during the
Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
SAN DIEGO and SUNNYVALE, Calif., April 14 /PRNewswire-FirstCall/ --
Pharmacyclics, Inc. (Nasdaq: PCYC ) today presented results from its
preclinical program evaluating PCI-32765, an orally available, selective
inhibitor of Bruton's tyrosine kinase, or Btk, in B-cell receptor (BCR)
Semafore's PI3 Kinase Inhibitor SF1126 is a Vascular Targeted Conjugate in Phase I Clinical Trials in Solid Tumors and Multiple Myeloma
SAN DIEGO, April 14 /PRNewswire/ -- Semafore Pharmaceuticals Inc.
announced today on the occasion of a poster presentation at the 2008 AACR
Annual Meeting that its integrin-targeted PI3 kinase inhibitor, SF1126, was
shown to cause significant tumor regression in combination with rapamycin
EntreMed to Highlight ENMD-2076 Kinase Inhibitor at 2008 AACR Annual Meeting
Oral Presentation During the "New Drugs on the Horizon 2" Special Session
ROCKVILLE, Md., April 11 /PRNewswire-FirstCall/ -- EntreMed, Inc.
(Nasdaq: ENMD ), a clinical-stage pharmaceutical company developing
therapeutics for the treatment of cancer and inflammatory diseases, today
CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
Pivotal phase II/III study demonstrates C1-INH is effective treatment for acute HAE attacks
KING OF PRUSSIA, Pa., March 6 /PRNewswire/ -- CSL Behring has submitted
a biologics license application (BLA) to the U.S. Food and Drug
Administration (FDA) requesting approval ...
NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference
NEW YORK, Feb. 22 /PRNewswire/ -- NexGenix Pharmaceuticals, presented
data on its Hsp90 inhibitor
program today at the GTCBio 5th Annual Cancer
Drugs Research & Development Conference taking place in Phoenix, Arizona.
The company presented data on NXD30001, one of several novel,
DHHS Guidelines Support Use of Trofile(TM) Assay Prior to CCR5 Inhibitor Use
SOUTH SAN FRANCISCO, Calif., Feb. 4 /PRNewswire-FirstCall/ -- Monogram
Biosciences, Inc. (Nasdaq: MGRM ) today announced that guidelines issued by
the Department of Health and Human Services (DHHS) recommend that a
co-receptor tropism test, such as Monogram's Trofile(TM) assay, should be
TargeGen Announces Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients
SAN DIEGO, Jan. 31 /PRNewswire/ -- TargeGen, Inc. today announced that
the Company has started a multi-center Phase I/II clinical trial of
TG101348, an oral, potent, and highly selective inhibitor
of JAK2 in
patients with myeloproliferative diseases.
JAK2 Inhibitor Shows Potent Activity in Cells From MPD Patients
Mayo clinic in key role in treatment discovery
MELBOURNE, Australia, Jan. 30 /PRNewswire/ -- Australian and New York
based company Cytopia Limited (ASX: CYT) announced today that its lead JAK2
inhibitor compound CYT387 has demonstrated potent activity in cells
isolated from patien...
Exelixis Presents Encouraging Phase 1 Data For XL019, A Novel Selective Inhibitor of JAK2
ATLANTA, Dec. 10 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq:
EXEL), today reported phase 1 data from an ongoing phase 1 trial of XL019
in patients with myelofibrosis, a myeloproliferative disorder (MPD). XL019
is an investigational small molecule that selectively inhibits the tyrosine
TargeGen Announces Planned Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients, and Presentations at ASH
SAN DIEGO, Dec. 6 /PRNewswire/ -- TargeGen, Inc. today announced that
the Company's recently submitted IND for TG101348 is now active and the
Company plans to initiate a multi-center clinical trial of TG101348, an
internally discovered, oral, potent, and highly selective JAK2 inhibitor